Polaroid Therapeutics
Polaroid Therapeutics is a Swiss-based biotech start-up, established in 2022 and incubated by the iconic Polaroid brand. The company is dedicated to addressing major challenges in antimicrobial therapies through cutting-edge technology and research. Its mission is to create a more human, meaningful, and healthier world by developing proprietary antimicrobial polymer technologies that reduce bioburden, improve patient outcomes, and do not trigger antimicrobial resistance (AMR). Polaroid Therapeutics focuses on advanced wound care, medical device coatings, and holistic therapeutic applications, aiming to set new standards in patient-centric care and global health.
What We Do
A proprietary, innovative polymer technology that disrupts bacterial cells with immediate and long-lasting activity, reducing bacterial bioburden without triggering antimicrobial resistance. Used in advanced wound dressings and medical device coatings.
Next-generation wound dressings leveraging proprietary antimicrobial polymers to prevent infection, aid healing, and address chronic and acute wounds. Includes novel carboxymethyl cellulose (CMC) dressings developed in partnership with SFM Limited.
Development of advanced antimicrobial therapies and wound care solutions that effectively address bioburden, including resistant strains, while ensuring patient safety and optimal healing outcomes.
Creation of long-lasting antimicrobial coatings for medical devices such as catheters and implants to reduce infection risks and combat antimicrobial resistance (AMR).
Application Area
Show LessRegenerative Medicine
Digital Health Technologies
Show More (3)Key People
News & Updates
Achievement of significant pre-clinical milestones in developing innovative medical devices using proprietary polymer technology that reduces bacterial bioburden without triggering antimicrobial resistance.
CEO Ran Frenkel discusses the company's vision to redefine healing, focusing on prevention, patient empowerment, and open-source collaboration to combat antimicrobial resistance and improve chronic wound care.
Announcement of Dr. Markus Rothmaier's appointment as Head of R&D, highlighting his role in advancing antibacterial technologies and product development.
Polaroid Therapeutics and The University of Hull have partnered to launch the world’s first £48M international Wound Innovation Centre (WIC), bringing together multidisciplinary experts to address critical issues in wound care and antimicrobial resistance.
Polaroid Therapeutics and SFM Limited are collaborating to develop a novel wound dressing that prevents infection and aids healing, leveraging proprietary antimicrobial polymer technology and advanced fibre technology.
Polaroid Therapeutics partners with Ingenix.AI to embed multimodal and multiscale agentic AI into clinical workflows, aiming to accelerate advanced patient-centred therapies and improve clinical trial outcomes.